Pharmacokinetics showed a profile consistent with once or twicedaily dosing. In patients with type 2 diabetes, PSN821 showed substantial andstatistically significant reductions in glucose responses to a standard nutrientchallenge of approximately 30% at 250mg and 500mg. The data from this study wassupportive of progression of PSN821 into a 14-day dosing ascending multiple dosestudy in healthy subjects and patients with type 2 diabetes and will besubmitted for presentation at a scientific meeting together with the data fromthe multiple ascending dose study. PSN602-101: Phase I DataIn the double-blind, placebo-controlled, ascending single and multiple dosefirst-in-human study, PSN602 was generally well tolerated at doses up to 20mgdaily for 14 days. At 30mg daily for 14 days, the incidence of adverse eventsincreased and one subject experienced syncope.
There were no clinicallyimportant adverse effects on laboratory tests, 12-lead ECGs or vital signs apartfrom post-dose postural tachycardia. Pharmacokinetics showed a profileconsistent with once daily dosing. In multiple dosing over 14 days inoverweight/obese subjects, PSN602 showed substantial and statisticallysignificant reductions from baseline in test meal intake of 36% and 25% at 20mgand 30mg respectively, comparing favourably with literature values forsibutramine of 15-25%. The data from this study is supportive of progression ofPSN602 into a 28-day dosing clinical study, at a top dose of 20mg daily, withweight loss as the primary endpoint and sibutramine as a comparator, and will bepresented at a scientific meeting. About OSI PharmaceuticalsOSI Pharmaceuticals is committed to “shaping medicine and changing lives” bydiscovering, developing and commercializing high-quality, novel anddifferentiated personalized medicines designed to extend life and improve thequality of life for patients with cancer and diabetes/obesity. For additionalinformation about OSI, please visit http:// This news release contains forward-looking statements.
(representing OSI)Justin Jackson/Kathy Nugent (media)212-213-0006 Copyright Business Wire 2009. BLOOMINGDALE, Ill.–(Business Wire)–PCTEL, Inc. (NASDAQ: PCTI), a leader in propagation and optimization solutionsfor the wireless industry, announced today that Marty Singer, PCTEL Chairman andCEO will present at the Robert W Baird 2009 Growth Stock Conference to be heldin Chicago. A live webcast of the presentation will be available at 1:55 p.m (CT) onWednesday, May 13, and will be archived for 90 days. The webcast can be accessedfrom the Investor page at or at http:// PCTELPCTEL, Inc.
(NASDAQ: PCTI), is a global leader in propagation and optimizationsolutions for the wireless industry. The company designs and developssoftware-based radios for wireless network optimization and develops anddistributes innovative antenna solutions. The company`s SeeGull® scanningreceivers, receiver-based products and CLARIFY® interference managementsolutions are used to measure, monitor and optimize cellular networks. PCTEL`sMAXRAD®, Bluewave and Wi-Sys antenna solutions address public safety, military,and government applications; SCADA, Health Care, Energy, Smart Grid andAgricultural applications; Indoor Wireless, Wireless Backhaul, and Cellularapplications. Its portfolio includes a broad range of WiMAX antennas, WiFiantennas, Land Mobile Radio antennas, and GPS antennas that serve innovativeapplications in telemetry, RFID, in-building, fleet management, and meshnetworks.
PCTEL provides parabolic antennas, ruggedized antennas, yagi antennas,and other high performance antennas for many applications. PCTEL`s products aresold worldwide through direct and indirect channels. For more information,please visit the company`s web site , ,, or PCTEL, Inc.Jack SellerPublic Relations(630)orSummit IR GroupMary McGowanInvestor Relations(408) Copyright Business Wire 2009. WASHINGTON (Reuters) – The Obama administration proposed on Monday to raise nearly $60 billion by closing loopholes including those related to the estate tax, and also revived a bid to cap itemized deductions wealthy individuals can claim.